子宫腺肌症患者的全身合并症研究
一项前瞻性观察研究比较了单纯子宫腺肌症患者(n=342)与子宫腺肌症合并子宫内膜异位症患者(n=347)的合并症情况。单纯子宫腺肌症患者的合并症患病率显著低于合并子宫内膜异位症者(44.7% vs 55.0%,P=0.007),自身免疫疾病和应激疼痛相关疾病均较少见。子宫内膜异位症共存与合并症存在独立关联(OR=1.65,95%CI 1.12-2.42;P=0.01)。
要点
- 单纯子宫腺肌症患者合并症患病率为44.7%(152/342),低于合并子宫内膜异位症者的55.0%(191/347)。
- 自身免疫疾病在单纯子宫腺肌症中占14%(48/342),低于合并组的23.9%(83/247)。
- 应激疼痛相关疾病在单纯子宫腺肌症中占30.4%(104/342),低于合并组的46.4%(161/347)。
核心结论
- 单纯子宫腺肌症患者合并症患病率低于子宫腺肌症合并子宫内膜异位症患者,提示两者临床特征不同。
- 作者认为需要更多流行病学数据来解释子宫腺肌症患者中某些全身合并症低患病率的现象。
研究设计与样本
- 前瞻性观察研究,比较单纯子宫腺肌症患者(n=342)与子宫腺肌症合并子宫内膜异位症患者(n=347)的合并症情况。
- 研究对象为20-50岁绝经前患者,排除患有恶性疾病者。
- 子宫内膜异位症或子宫腺肌症的诊断通过经阴道超声、磁共振成像或手术做出。
- 合并症分为自身免疫疾病和应激疼痛相关疾病两类。
主要发现
- 单纯子宫腺肌症组合并症患病率为44.7%(152/342),合并子宫内膜异位症组为55.0%(191/34),P=0.007。
- 自身免疫疾病在单纯子宫腺肌症组为14%(48/342),在合并子宫内膜异位症组为23.9%(83/247),P=0.001。
- 应激疼痛相关疾病在单纯子宫腺肌症组为30.4%(104/342),在合并子宫内膜异位症组为46.4%(161/347),P<0.001。
- 年龄>35岁的单纯子宫腺肌症患者自身免疫合并症比例为5.8%(20/48),低于合并子宫内膜异位症患者的12.6%(44/347),P=0.002。
- 在子宫腺肌症患者中,子宫内膜异位症共存与合并症存在独立关联(OR=1.65,95%CI 1.12-2.42;P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: How do comorbidities and their prevalence differ between patients with adenomyosis alone and patients with both adenomyosis and endometriosis? DESIGN: A prospective observational study compared the presence of comorbidities between patients with adenomyosis alone (n = 342) and patients with both adenomyosis and endometriosis (n = 347). Premenopausal patients aged 20-50 years, excluding those with malignant diseases, were studied. The diagnosis of endometriosis or adenomyosis was made by transvaginal ultrasound, magnetic resonance imaging or surgery. Comorbidities were classified as either (i) autoimmune or (ii) stress- and pain-related. RESULTS: Patients with adenomyosis alone had a significantly lower prevalence of comorbidities compared with patients with both adenomyosis and endometriosis [44.7% (152/342) versus 55.0% (191/34); P = 0.007]. Autoimmune diseases [14% (48/342) versus 23.9% (83/247); P = 0.001] and stress- and pain-related disorders [30.4% (104/342) versus 46.4% (161/347); P < 0.001] were less common in patients with adenomyosis alone compared with patients with both adenomyosis and endometriosis. Patients aged >35 years with adenomyosis alone were less likely to have autoimmune comorbidities compared with patients with both adenomyosis and endometriosis [5.8% (20/48) versus 12.6% (44/347); P = 0.002]. Co-existence of endometriosis was independently associated with the presence of comorbidities among patients with adenomyosis (OR = 1.65, 95% CI 1.12-2.42; P = 0.01). CONCLUSIONS: Patients with adenomyosis alone had a lower prevalence of comorbidities compared with patients with both adenomyosis and endometriosis, suggesting a different clinical profile. More epidemiological data will be useful to explain the low prevalence of some systemic comorbidities in patients with adenomyosis.
引用
- Gallone A, Vannuccini S, Manzi V, et al. Systemic comorbidities in patients with adenomyosis. Reprod Biomed Online. 2025. PMID: 41176881. doi:10.1016/j.rbmo.2025.105102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。